LabGenomics Co. Ltd (084650) Fair Value & Analysis
Healthcare · KR · Market cap 48.2B KRW
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 6 days ago
Fair value updated Aug 13, 2026, revised from 1,350 KRW to 672.29 KRW (−50.2%) since Jul 22, 2026. Share price −4.3% over the past month.
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (501.71 KRW to 1,003 KRW) leaves room in how you read the outcome.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 530.00 KRW – 6,100 KRW · fair‑value band 501.71 KRW – 1,003 KRW · the 620.00 KRW price screens below the 672.29 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
LabGenomics Co. Ltd (084650) currently trades at 620.00 KRW, while our model-based Fair Value estimate is 672.29 KRW, implying the stock looks roughly 8.4% fairly valued today. The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, LabGenomics Co. Ltd generated revenue of 187B KRW at a net margin of 39.7%. Revenue declined 54.1% year over year. Net debt stands at 41.9B KRW. Fundamentals as of Aug 13, 2026
Our scenario range runs from 501.71 KRW (bear case) to 1,003 KRW (bull case); at 620.00 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 79% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -35% fair-value upside, at 8%, 084650 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 084650 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 37 · Market factors (momentum, volatility) 15
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
LabGenomics Co., Ltd. engages in the research and development of biotechnology products in South Korea. It is also involved in the sale of diagnostic devices. The company was founded in 2002 and is based in Seongnam-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
LabGenomics Co. Ltd reported revenue of 88.2B KRW in FY2025 versus 202B KRW in FY2021, a compound −18.8%/yr. Reported net income was −64.4B KRW in FY2025.
Watch 084650: get an alert when its fair value changes →
Peer Group
Health Care · 2296 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Providers & Services” was too small, so the broader sector is used.)
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Healthcare Providers & Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Novartis AG NVSN | 2,742 MXN | 1,964 MXN | -28% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Samsung Biologics Co 207940 | 1,549,000 KRW | 1,055,793 KRW | -32% |
| Bayer Aktiengesellschaft BAYER | 17,685 HUF | 14,810 HUF | -16% |
| Celltrion, Inc 068270 | 202,000 KRW | 74,519 KRW | -63% |
| Divi's Laboratories Limited DIVISLAB | ₹8,525 | ₹1,228 | -86% |
| ALTEOGEN Inc 196170 | 314,000 KRW | 39,476 KRW | -87% |
| SK Biopharmaceuticals Co 326030 | 85,300 KRW | 55,217 KRW | -35% |
| Yuhan Corporation 000100 | 83,100 KRW | 38,995 KRW | -53% |
| Hanmi Pharm. Co 128940 | 398,500 KRW | 273,222 KRW | -31% |
Compare LabGenomics Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is LabGenomics Co. Ltd (084650) overvalued or undervalued?
What is the fair value of 084650?
What is the quality score of 084650?
What is the revenue of LabGenomics Co. Ltd (084650)?
What is the net profit margin of 084650?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track LabGenomics Co. Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.